Istradefylline, an adenosine A2a receptor antagonist, inhibits the CD4⁺ T-cell hypersecretion of IL-17A and IL-8 in humans

Mieko Tokanoa Departments of Allergy and Immunology, Faculty of Medicine, Saitama Medical University, Moroyama, Japan;b Department of Infectious Disease and Infection Control, Saitama Medical University, Moroyama, JapanView further author information

Masaaki Kawanoa Departments of Allergy and Immunology, Faculty of Medicine, Saitama Medical University, Moroyama, JapanView further author information

Rie Takagia Departments of Allergy and Immunology, Faculty of Medicine, Saitama Medical University, Moroyama, JapanView further author information

Sho Matsushitaa Departments of Allergy and Immunology, Faculty of Medicine, Saitama Medical University, Moroyama, Japan;c Allergy Center, Saitama Medical University, Moroyama, JapanCorrespondence[email protected]

https://orcid.org/0000-0003-4810-1065 View further author information

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Istradefylline, an adenosine A2a receptor antagonist, inhibits the CD4⁺ T-cell hypersecretion of IL-17A and IL-8 in humans

Articles from other publishers (2)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Istradefylline, an adenosine A2a receptor antagonist, inhibits the CD4+ T-cell hypersecretion of IL-17A and IL-8 in humans

Citations (2)

Articles from other publishers (2)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Istradefylline, an adenosine A2a receptor antagonist, inhibits the CD4⁺ T-cell hypersecretion of IL-17A and IL-8 in humans